178 related articles for article (PubMed ID: 16524972)
1. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study.
Iacopetta B; Russo A; Bazan V; Dardanoni G; Gebbia N; Soussi T; Kerr D; Elsaleh H; Soong R; Kandioler D; Janschek E; Kappel S; Lung M; Leung CS; Ko JM; Yuen S; Ho J; Leung SY; Crapez E; Duffour J; Ychou M; Leahy DT; O'Donoghue DP; Agnese V; Cascio S; Di Fede G; Chieco-Bianchi L; Bertorelle R; Belluco C; Giaretti W; Castagnola P; Ricevuto E; Ficorella C; Bosari S; Arizzi CD; Miyaki M; Onda M; Kampman E; Diergaarde B; Royds J; Lothe RA; Diep CB; Meling GI; Ostrowski J; Trzeciak L; Guzinska-Ustymowicz K; Zalewski B; Capellá GM; Moreno V; Peinado MA; Lönnroth C; Lundholm K; Sun XF; Jansson A; Bouzourene H; Hsieh LL; Tang R; Smith DR; Allen-Mersh TG; Khan ZA; Shorthouse AJ; Silverman ML; Kato S; Ishioka C;
Ann Oncol; 2006 May; 17(5):842-7. PubMed ID: 16524972
[TBL] [Abstract][Full Text] [Related]
2. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
Russo A; Bazan V; Iacopetta B; Kerr D; Soussi T; Gebbia N;
J Clin Oncol; 2005 Oct; 23(30):7518-28. PubMed ID: 16172461
[TBL] [Abstract][Full Text] [Related]
3. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of K-ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer.
Bleeker WA; Hayes VM; Karrenbeld A; Hofstra RM; Verlind E; Hermans J; Poppema S; Buys CH; Plukker JT
Dis Colon Rectum; 2001 Mar; 44(3):358-63. PubMed ID: 11289281
[TBL] [Abstract][Full Text] [Related]
5. Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study.
Bazan V; Agnese V; Corsale S; Calò V; Valerio MR; Latteri MA; Vieni S; Grassi N; Cicero G; Dardanoni G; Tomasino RM; Colucci G; Gebbia N; Russo A;
Ann Oncol; 2005 May; 16 Suppl 4():iv50-55. PubMed ID: 15923430
[TBL] [Abstract][Full Text] [Related]
6. Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer.
Bleeker WA; Hayes VM; Karrenbeld A; Hofstra RM; Hermans J; Buys CC; Plukker JT
Am J Gastroenterol; 2000 Oct; 95(10):2953-7. PubMed ID: 11051374
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis.
Ma X; Le Teuff G; Lacas B; Tsao MS; Graziano S; Pignon JP; Douillard JY; Le Chevalier T; Seymour L; Filipits M; Pirker R; Jänne PA; Shepherd FA; Brambilla E; Soria JC; Hainaut P;
J Thorac Oncol; 2016 Jun; 11(6):850-61. PubMed ID: 26899019
[TBL] [Abstract][Full Text] [Related]
8. Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy.
Godai TI; Suda T; Sugano N; Tsuchida K; Shiozawa M; Sekiguchi H; Sekiyama A; Yoshihara M; Matsukuma S; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Miyagi Y
BMC Cancer; 2009 Dec; 9():420. PubMed ID: 19954513
[TBL] [Abstract][Full Text] [Related]
9. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
[TBL] [Abstract][Full Text] [Related]
10. TP53 mutations in advanced colorectal cancer: the dark side of the moon.
Pietrantonio F; Biondani P; Perrone F; Di Bartolomeo M; Pacifici M; Milione M; Melotti F; Maggi C; Montemurro G; Bossi I; Mariani L; de Braud F
Oncology; 2014; 86(5-6):289-94. PubMed ID: 24924261
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.
Russo A; Bazan V; Agnese V; Rodolico V; Gebbia N
Ann Oncol; 2005 May; 16 Suppl 4():iv44-49. PubMed ID: 15923428
[TBL] [Abstract][Full Text] [Related]
12. Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection.
Molleví DG; Serrano T; Ginestà MM; Valls J; Torras J; Navarro M; Ramos E; Germà JR; Jaurrieta E; Moreno V; Figueras J; Capellà G; Villanueva A
Carcinogenesis; 2007 Jun; 28(6):1241-6. PubMed ID: 17259658
[TBL] [Abstract][Full Text] [Related]
13.
Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
[TBL] [Abstract][Full Text] [Related]
14. Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer.
Gnanasampanthan G; Elsaleh H; McCaul K; Iacopetta B
J Pathol; 2001 Dec; 195(5):543-8. PubMed ID: 11745689
[TBL] [Abstract][Full Text] [Related]
15. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location.
Gervaz P; Bouzourene H; Cerottini JP; Chaubert P; Benhattar J; Secic M; Wexner S; Givel JC; Belin B
Dis Colon Rectum; 2001 Mar; 44(3):364-72; discussion 372-3. PubMed ID: 11289282
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation.
Soong R; Powell B; Elsaleh H; Gnanasampanthan G; Smith DR; Goh HS; Joseph D; Iacopetta B
Eur J Cancer; 2000 Oct; 36(16):2053-60. PubMed ID: 11044641
[TBL] [Abstract][Full Text] [Related]
17. Genetic tumor markers with prognostic impact in Dukes' stages B and C colorectal cancer patients.
Diep CB; Thorstensen L; Meling GI; Skovlund E; Rognum TO; Lothe RA
J Clin Oncol; 2003 Mar; 21(5):820-9. PubMed ID: 12610180
[TBL] [Abstract][Full Text] [Related]
18. A systematic overview of chemotherapy effects in colorectal cancer.
Ragnhammar P; Hafström L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
[TBL] [Abstract][Full Text] [Related]
19. DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study.
Bazan V; Migliavacca M; Zanna I; Tubiolo C; Corsale S; Calò V; Amato A; Cammareri P; Latteri F; Grassi N; Fulfaro F; Porcasi R; Morello V; Nuara RB; Dardanoni G; Salerno S; Valerio MR; Dusonchet L; Gerbino A; Gebbia N; Tomasino RM; Russo A
J Cancer Res Clin Oncol; 2002 Dec; 128(12):650-8. PubMed ID: 12474051
[TBL] [Abstract][Full Text] [Related]
20. The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.
Kandioler D; Schoppmann SF; Zwrtek R; Kappel S; Wolf B; Mittlböck M; Kührer I; Hejna M; Pluschnig U; Ba-Ssalamah A; Wrba F; Zacherl J
J Thorac Cardiovasc Surg; 2014 Nov; 148(5):2280-6. PubMed ID: 25135238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
